Toward a unified model of passive drug permeation II: The physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1599-1610

  Ghosh, Avijit ^a   Maurer, Tristan S ^a   Litchfield, John ^a   Varma, Manthema V ^a   Rotter, Charles ^a   Scialis, Renato ^a   Feng, Bo ^a   Tu, Meihua ^b   Guimaraes, Cris R W ^b   Scott, Dennis O ^a  

^a PFIZER INC   (United States)

^b Pfizer Worldwide Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; GLUCOKINASE; HEPATOSELECTIVE GLUCOKINASE ACTIVATOR; ORGANIC ANION TRANSPORTER; UNCLASSIFIED DRUG; 6-(2-(4-(CYCLOBUTANESULFONYL)-1H-IMIDAZOL-1-YL)-3-CYCLOPENTYLPROPANAMIDO)PYRIDINE-3-CARBOXYLIC ACID; 6-(3-CYCLOPENTYL-2-(4-TRIFLUOROMETHYL)-1H-IMIDAZOL-1-YL)PROPANAMIDO)NICOTINIC ACID; IMIDAZOLE DERIVATIVE; NICOTINIC ACID;

ANALYTIC METHOD; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG PENETRATION; ELECTROCHEMISTRY; ENZYME PHOSPHORYLATION; FICK NERNST PLANCK METHOD; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZATION; MATHEMATICAL MODEL; NERNST PLANCK EQUATION; PANCREAS; PH; TISSUE DISTRIBUTION; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; LIVER; METABOLISM; MUSCLE; PERMEABILITY; RAT;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; DRUG DESIGN; ENZYME ACTIVATORS; GLUCOKINASE; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; LIVER; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MUSCLES; NIACIN; PANCREAS; PERMEABILITY; RATS; TISSUE DISTRIBUTION;

EID: 84907587750     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058032     Document Type: Article

References (48)

1. Avdeef A (2012) Absorption and Drug Development: Solubility, Permeability, and Charge State, 2nd ed, John Wiley & Sons, Hoboken, NJ.
2. Becke AD (1993) A new mixing of Hartree-Fock and local density-functional theories. J Chem Phys 98:1372-1377.
3. Bochevarov AD, Harder E, Hughes TF, Greenwood JR, Braden DA, Philipp DM, Rinaldo D, Halls MD, Zhang J, and Friesner RA (2013) Jaguar: a high-performance quantum chemistry software program with strengths in life and materials sciences. Int J Quantum Chem 113: 2110-2142.
4. Clark DE (2003) In silico prediction of blood-brain barrier permeation. Drug Discov Today 8: 927-933.
5. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, and Gebhard DF, et al. (2011) Developement of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci 100:4974-4985.
6. Dobson PD and Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:205-220.
7. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, and Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353-362.
8. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, and Antonsson M (2009) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
9. Frisch MJ, Pople JA, and Binkley JS (1984) Self-consistent molecular orbital methods 25: supplementary functions for Gaussian basis sets. J Chem Phys 80:3265-3269.
10. Ghosh A, Scott DO, and Maurer TS (2014) Towards a unified model of passive drug permeation I: origins of the unstirred water layer with applications to ionic permeation. Eur J Pharm Sci 52:109-124.
11. Grimsby J, Sarabu R, Corbett WL, Haynes N-E, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, and Mahaney PE, et al. (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373.
12. Guderley H, Houle-Leroy P, Diffee GMG, Camp DMD, and Garland T, Jr (2006) Morphometry, ultrastructure, myosin isoforms, and metabolic capacities of the "mini muscles" favoured by selection for high activity in house mice. Comp Biochem Physiol B Biochem Mol Biol 144: 271-282.
13. Hickey JL, Ruhayel RA, Barnard PJ, Baker MV, Berners-Price SJ, and Filipovska A (2008) Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc 130:12570-12571.
14. Hockings PD and Rogers PJ (1996) The measurement of transmembrane electrical potential with lipophilic cations. Biochim Biophys Acta 1282:101-106.
15. Ishikawa T, Marunaka Y, and Rotin D (1998) Electrophysiological characterization of the rat epithelial Na+ channel (rENaC) expressed in MDCK cells: effects of Na+ and Ca2+. J Gen Physiol 111:825-846.
16. Jorgensen WL, Maxwell DS, and Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236.
17. Kaminski GA, Friesner RA, Tirado-Rives J, and Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105:6474-6487.
18. Kaufmann AM and Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96:729-746.
19. Kell DB, Dobson PD, and Oliver SG (2011) Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today 16: 704-714.
20. Lobell M, Molnár L, and Keserü GM (2003) Recent advances in the prediction of blood-brain partitioning from molecular structure. J Pharm Sci 92:360-370.
21. Marten B, Kim K, Cortis C, Friesner RA, Murphy RB, Ringnalda MN, Sitkoff D, and Honig B (1996) New model for calculation of solvation free energies: correction of self-consistent reaction field continuum dielectric theory for short-range hydrogen-bonding effects. J Phys Chem 100:11775-11788.
22. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399-416.
23. Matschinsky FM (2013) GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 34:90-99.
24. Modica-Napolitano JS and Singh KK (2002) Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med 4:1-19.
25. Morgan RG, Schaeffer BK, and Longnecker DS (1986) Size and number of nuclei differ in normal and neoplastic acinar cells from rat pancreas. Pancreas 1:37-43.
26. Nishiyama A and Petersen OH (1974) Pancreatic acinar cells: membrane potential and resistance change evoked by acetylcholine. J Physiol 238:145-158.
27. Palm K, Luthman K, Ros J, Grasjo J, and Artursson P (1999) Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther 291:435-443.
28. Peters R (1984) Nucleo-cytoplasmic flux and intracellular mobility in single hepatocytes measured by fluorescence microphotolysis. EMBO J 3:1831-1836.
29. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, and Tu M, et al. (2012a) Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55: 1318-1333.
30. Pfefferkorn JA, Tu M, Filipski KJ, Guzman-Perez A, Bian J, Aspnes GE, Sammons MF, Song W, Li J-C, and Jones CS, et al. (2012b) The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 22:7100-7105.
31. Plettenberg S, Weiss EC, Lemor R, and Wehner F (2008) Subunits alpha, beta and gamma of the epithelial Na+ channel (ENaC) are functionally related to the hypertonicity-induced cation channel (HICC) in rat hepatocytes. Pflugers Arch 455:1089-1095.
32. Ribeiro MMB, Domingues MM, Freire JM, Santos NC, and Castanho MARB (2012) Translocating the blood-brain barrier using electrostatics. Front Cell Neurosci 6:1-7.
33. Saito S, Murakami Y, Miyauchi S, and Kamo N (1992) Measurement of plasma membrane potential in isolated rat hepatocytes using the lipophilic cation, tetraphenylphosphonium: correction of probe intracellular binding and mitochondrial accumulation. Biochim Biophys Acta 1111:221-230.
34. Sawant A, Garland SJ, House AA, and Overend TJ (2011) Morphological, electrophysiological, and metabolic characteristics of skeletal muscle in people with end-stage renal disease: a critical review. Physiother Can 63:355-376.
35. Schanker LS (1962) Passage of drugs across body membranes. Pharmacol Rev 14:501-530.
36. Shore PA, Brodie BB, and Hogben CA (1957) The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 119:361-369.
37. Simmons NL (1984) Epithelial cell volume regulation in hypotonic fluids: studies using a model tissue culture renal epithelial cell system. Q J Exp Physiol 69:83-95.
38. Stephens PJ, Devlin FJ, and Chabalowski CF (1994) Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. J Phys Chem 98: 11623-11627.
39. Stevens BD, Litchfield J, Pfefferkorn JA, Atkinson K, Perreault C, Amor P, Bahnck K, Berliner MA, Calloway J, and Carlo A, et al. (2013) Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia. Bioorg Med Chem Lett 23: 6588-6592.
40. Still WC, Tempczyk A, Hawley RC, and Hendrickson T (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112:6127-6129.
41. Søgaard R, Ljungstrøm T, Pedersen KA, Olesen SP, and Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 280:C859-C866.
42. Taga R, Alvares EP, and Sesso A (1993) Morphometric studies on terminal tubule and acinar cells in developing submandibular gland of the rat. Arch Histol Cytol 56:517-523.
43. Tamai I, Sai Y, Kobayashi H, Kamata M, Wakamiya T, and Tsuji A (1997) Structureinternalization relationship for adsorptive-mediated endocytosis of basic peptides at the bloodbrain barrier. J Pharmacol Exp Ther 280:410-415.
44. Tannor DJ, Marten B, and Murphy R (1994) Accurate first principles calculation of molecular charge distributions and solvation energies from ab initio quantum mechanics and continuum dielectric theory. J Am Chem Soc 116:11875-11882.
45. Trapp S and Horobin RW (2005) A predictive model for the selective accumulation of chemicals in tumor cells. Eur Biophys J 34:959-966.
46. Trapp S, Rosania GR, Horobin RW, and Kornhuber J (2008) Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 37:1317-1328.
47. Tsuji A (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2:54-62.
48. Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, Litchfield J, Goosen TC, and El-Kattan AF (2011) pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 8:1303-1313.